BioSpace News Archive

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 32nd Annual ROTH Conference.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the company will host a conference call on Thursday, March 12, 2020, at 8:00 a.m. ET to discuss financial results for the quarter and year ended December 31, 2019 and provide a corporate update

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call.

Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, and company management will participate in the following healthcare investor conferences: 32nd Annual ROTH Conference Panel Presentation Date and Time: March 16, 2020

Aspera, the leading global provider of solutions and services for Software Asset Management (SAM) and part of the USU Group, today announced that the National Institutes of Health (NIH) has signed a $5 million agreement to use Aspera SAM services

Genesis HealthCare (NYSE:GEN) (Genesis or the Company) today announced that it expects to release its fourth quarter and year end December 31, 2019 results before the market opens on Thursday, March 12, 2020.

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with respiratory conditions including, serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors, will host an analyst day in New York City, March 5, 2020.

Approval of the new delivery system follows first implants of the company’s next-generation and investigational Navitor™ TAVI valve

Presented at The International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting, results from three pivotal, randomized, placebo-controlled trials assessing efficacy of Addyi in treating premenopausal women with Hypoactive Sexual Desire Disorder, or HSDD, show clear benefits in multiple areas of female sexual function in as early as 4 weeks and maintained for duration of treatment.

New tool significantly increases HDR rates by providing optimized donor template design and simplified Cas9 guide RNA selection